Palavra, Filipe

Defining high, medium, and low impact prognostic factors for developing multiple sclerosis

Tintore, M., Rovira, À., Río, J., Otero-Romero, S., Arrambide, G., Tur, C., Comabella, M., Nos, C., Arévalo, M. J., Negrotto, L., et al. (2015) · Brain

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 530

Defining milestones for the study of remyelination using the cuprizone mouse model: How early is early?

Palavra, F., Viana, S. D., Henriques, S., Dinis, J., Martins, J., Madeira, M. H., Santiago, R., Petrella, L., Sereno, J., Castelo-Branco, M., et al. (2022) · Multiple Sclerosis and Related Disorders

Multiple Sclerosis Research StudiesNeurogenesis and neuroplasticity mechanisms

Cited by 14

Should we systematically test patients with clinically isolated syndrome for auto-antibodies?

Negrotto, L., Tur, C., Tintoré, M., Arrambide, G., Sastre-Garriga, J., Río, J., Comabella, M., Nos, C., Galán, I., Vidal-Jordana, A., et al. (2015) · Multiple Sclerosis Journal

Multiple Sclerosis Research StudiesSystemic Lupus Erythematosus Research

Cited by 11